MX2014010417A - Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. - Google Patents
Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.Info
- Publication number
- MX2014010417A MX2014010417A MX2014010417A MX2014010417A MX2014010417A MX 2014010417 A MX2014010417 A MX 2014010417A MX 2014010417 A MX2014010417 A MX 2014010417A MX 2014010417 A MX2014010417 A MX 2014010417A MX 2014010417 A MX2014010417 A MX 2014010417A
- Authority
- MX
- Mexico
- Prior art keywords
- booster vaccines
- adjuvanted formulations
- vaccines
- adjuvanted
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La invención mejora las vacunas TdaP al incluir un agonista de TLR en ellas. Este agonista puede proveer protección más fuerte, protección de duración más larga, y/o puede reducir la cantidad de antígeno que se requiere para lograr una respuesta inmunológica particular.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261608398P | 2012-03-08 | 2012-03-08 | |
US201261697730P | 2012-09-06 | 2012-09-06 | |
PCT/EP2013/054672 WO2013132041A2 (en) | 2012-03-08 | 2013-03-08 | Adjuvanted formulations of booster vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014010417A true MX2014010417A (es) | 2014-09-22 |
Family
ID=47843287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014010417A MX2014010417A (es) | 2012-03-08 | 2013-03-08 | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. |
Country Status (9)
Country | Link |
---|---|
US (3) | US9375471B2 (es) |
EP (1) | EP2822581A2 (es) |
JP (5) | JP6345603B2 (es) |
CN (1) | CN104159602B (es) |
AU (1) | AU2013229432A1 (es) |
CA (1) | CA2866406A1 (es) |
MX (1) | MX2014010417A (es) |
RU (1) | RU2014140521A (es) |
WO (1) | WO2013132041A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
MX2012002723A (es) * | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
US20120177681A1 (en) | 2010-09-01 | 2012-07-12 | Manmohan Singh | Formulation of immunopotentiators |
RU2013144207A (ru) * | 2011-03-02 | 2015-04-10 | Новартис Аг | Комбинированные вакцины с пониженными дозами антигена и/или адъюванта |
KR20140066212A (ko) * | 2011-09-01 | 2014-05-30 | 노파르티스 아게 | 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물 |
JP6345603B2 (ja) | 2012-03-08 | 2018-06-20 | ノバルティス アーゲー | 追加免疫ワクチンのアジュバント化された処方物 |
US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
CA2942450A1 (en) | 2014-03-26 | 2015-10-01 | Glaxosmithkline Biologicals S.A. | Mutant staphylococcal antigens |
AU2015287773B2 (en) | 2014-07-11 | 2018-03-29 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
CN106715431A (zh) | 2014-09-16 | 2017-05-24 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
JP7195148B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Tlrアゴニストを含有する製剤及び使用方法 |
US20220054615A1 (en) * | 2018-12-05 | 2022-02-24 | Sanofi Pasteur Inc. | Pertussis booster vaccine |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5059258A (en) | 1989-08-23 | 1991-10-22 | Aluminum Company Of America | Phosphonic/phosphinic acid bonded to aluminum hydroxide layer |
IT1248735B (it) * | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
AU3630093A (en) | 1992-03-02 | 1993-10-05 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
GB2303855B (en) | 1994-07-01 | 1998-10-28 | Rican Limited | Helicobacter pylori antigenic protein preparation and immunoassays |
WO1996016046A2 (en) | 1994-11-24 | 1996-05-30 | F. Hoffmann-La Roche Ag | Novel benzyl pyrimidines |
WO1997025429A1 (en) | 1996-01-04 | 1997-07-17 | Rican Limited | Helicobacter pylori bacterioferritin |
GB9623233D0 (en) * | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
CN1306438A (zh) | 1998-05-07 | 2001-08-01 | 科里克萨有限公司 | 佐剂组合物及其使用方法 |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
DE10012370A1 (de) * | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
EP1297005B1 (en) | 2000-07-03 | 2009-08-26 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia pneumoniae |
FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
DE60228758D1 (de) | 2001-12-12 | 2008-10-16 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia tracheomatis |
GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
AU2003274511B2 (en) | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
US7818252B2 (en) | 2003-02-20 | 2010-10-19 | Gilat Satellite Networks, Ltd | Enforcement of network service level agreements |
JP5280631B2 (ja) | 2003-06-16 | 2013-09-04 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー, アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック | 抗ウイルスヌクレオチド類似物としてのホスホネート基を有するピリミジン化合物 |
EP1635865A2 (en) | 2003-06-26 | 2006-03-22 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
CA2557353A1 (en) | 2004-03-02 | 2005-09-15 | Chiron Corporation | Immunogenic compositions for chlamydia pneunomiae |
GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
EP1732384A4 (en) | 2004-03-31 | 2008-04-23 | Univ New York State Res Found | NOVEL SYNTHETIC C-GLYCOLIPIDES, THEIR SYNTHESIS AND USE FOR THE TREATMENT OF INFECTIONS, CANCER AND AUTOIMMUNE DISEASES |
NZ550152A (en) | 2004-04-05 | 2009-04-30 | Pfizer Prod Inc | Microfluidized oil-in-water emulsions and vaccine compositions |
HUE027400T2 (en) | 2005-02-18 | 2016-10-28 | Glaxosmithkline Biologicals Sa | Proteins and nucleic acids from meningitis / sepsis with Escherichia coli |
NZ560929A (en) | 2005-02-18 | 2009-12-24 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
US8222257B2 (en) | 2005-04-01 | 2012-07-17 | The Regents Of The University Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
CN101238146A (zh) | 2005-05-12 | 2008-08-06 | 诺华疫苗和诊断有限公司 | 砂眼衣原体的免疫原性组合物 |
US8329184B2 (en) | 2005-06-27 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Process for manufacturing vaccines |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
JPWO2007034916A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
JPWO2007034881A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
WO2007034817A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
WO2007053455A2 (en) | 2005-10-28 | 2007-05-10 | Vaxinnate Corporation | Polypeptide ligans for toll-like receptor 4 (tlr4) |
JP2009514839A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | サイトカイン誘導剤を含むアジュバントインフルエンザワクチン |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
CA2633142A1 (en) | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, S.R.L. | Chlamydial antigens |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
AU2007216247A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as TLR7 modulators |
EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
CA2646891A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
AU2007269557B2 (en) | 2006-07-07 | 2013-11-07 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
GB0616306D0 (en) * | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
EA016417B1 (ru) | 2006-09-07 | 2012-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ получения вакцины |
WO2008043774A1 (en) | 2006-10-12 | 2008-04-17 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
GB0622282D0 (en) | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
TW200843779A (en) | 2007-02-19 | 2008-11-16 | Smithkline Beecham Corp | Compounds |
AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
EP2155743B1 (en) | 2007-05-08 | 2012-08-29 | AstraZeneca AB | Imidazoquinolines with immuno-modulating properties |
AU2008259423A1 (en) * | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
ATE501136T1 (de) | 2007-08-03 | 2011-03-15 | Pfizer Ltd | Imidazopyridinone |
SI2200642T1 (sl) | 2007-10-19 | 2012-06-29 | Novartis Ag | Formulacije meningokoknega cepiva |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
WO2009081172A1 (en) | 2007-12-24 | 2009-07-02 | Novartis Ag | Assays for adsorbed influenza vaccines |
US8092813B1 (en) | 2007-12-28 | 2012-01-10 | Novartis Ag | Polychlorinated biphenyls and squalene-containing adjuvants |
CN102015651B (zh) | 2008-03-03 | 2014-12-31 | Irm责任有限公司 | 作为tlr活性调节剂的化合物和组合物 |
EP2386557B1 (en) | 2008-03-24 | 2018-01-10 | 4SC Discovery GmbH | Novel substituted imidazoquinolines |
EP2303236A4 (en) | 2008-07-01 | 2012-09-26 | Univ Emory | SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS |
DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
CA2735404C (en) | 2008-08-28 | 2013-04-16 | Novartis Ag | Production of squalene from hyper-producing yeasts |
TWM352127U (en) | 2008-08-29 | 2009-03-01 | Bestac Advanced Material Co Ltd | Polishing pad |
CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
PE20110992A1 (es) | 2009-02-17 | 2012-02-12 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende un antigeno del virus del dengue |
EP2510947B1 (en) | 2009-04-14 | 2016-02-10 | GlaxoSmithKline Biologicals SA | Compositions for immunising against Staphylococcus aureus |
EP2437777B1 (en) | 2009-06-01 | 2014-09-17 | Novartis AG | COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES |
CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
NZ598458A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
MX2012002723A (es) | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
AU2010314861A1 (en) | 2009-11-09 | 2012-07-05 | National Jewish Health | Vaccine composition |
CA2782650C (en) | 2009-12-03 | 2014-02-04 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
SI2601933T1 (sl) | 2009-12-03 | 2015-12-31 | Novartis Ag | Hidrofilna filtracija med izdelavo adjuvantov za cepiva |
JP5820390B2 (ja) | 2009-12-03 | 2015-11-24 | ノバルティス アーゲー | エマルジョンの微小流動化中および/または均質化中における成分の循環 |
KR101853513B1 (ko) | 2010-03-23 | 2018-04-30 | 노파르티스 아게 | 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 tlr2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물 |
WO2011130379A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
CN105125488A (zh) | 2010-05-12 | 2015-12-09 | 诺华股份有限公司 | 制备鲨烯的改良方法 |
GB201009673D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
GB201009676D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
GB201009671D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
US20120177681A1 (en) | 2010-09-01 | 2012-07-12 | Manmohan Singh | Formulation of immunopotentiators |
ES2630029T3 (es) | 2010-12-14 | 2017-08-17 | Glaxosmithkline Biologicals Sa | Análisis de citometría de flujo de materiales adsorbidos en sales metálicas |
RU2013144207A (ru) | 2011-03-02 | 2015-04-10 | Новартис Аг | Комбинированные вакцины с пониженными дозами антигена и/или адъюванта |
KR20140066212A (ko) | 2011-09-01 | 2014-05-30 | 노파르티스 아게 | 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물 |
WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
EP2822589A1 (en) | 2012-03-07 | 2015-01-14 | Novartis AG | Adjuvanted formulations of rabies virus immunogens |
LT2822947T (lt) | 2012-03-07 | 2016-10-10 | Glaxosmithkline Biologicals Sa | Tlr7 agonisto arginino druskos |
JP6345603B2 (ja) | 2012-03-08 | 2018-06-20 | ノバルティス アーゲー | 追加免疫ワクチンのアジュバント化された処方物 |
JP6324961B2 (ja) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン |
WO2014064229A1 (en) | 2012-10-25 | 2014-05-01 | Novartis Ag | Nicotinamide as adjuvant |
-
2013
- 2013-03-08 JP JP2014560382A patent/JP6345603B2/ja active Active
- 2013-03-08 CA CA2866406A patent/CA2866406A1/en not_active Abandoned
- 2013-03-08 RU RU2014140521A patent/RU2014140521A/ru not_active Application Discontinuation
- 2013-03-08 EP EP13708155.0A patent/EP2822581A2/en not_active Withdrawn
- 2013-03-08 AU AU2013229432A patent/AU2013229432A1/en not_active Abandoned
- 2013-03-08 WO PCT/EP2013/054672 patent/WO2013132041A2/en active Application Filing
- 2013-03-08 CN CN201380012817.4A patent/CN104159602B/zh active Active
- 2013-03-08 US US13/790,948 patent/US9375471B2/en active Active
- 2013-03-08 MX MX2014010417A patent/MX2014010417A/es active IP Right Grant
-
2016
- 2016-05-24 US US15/163,592 patent/US9931399B2/en active Active
-
2017
- 2017-05-15 JP JP2017096343A patent/JP2017132821A/ja not_active Withdrawn
-
2018
- 2018-02-26 US US15/905,483 patent/US10842868B2/en active Active
- 2018-10-15 JP JP2018194314A patent/JP2019001832A/ja active Pending
-
2021
- 2021-02-02 JP JP2021015094A patent/JP7295895B2/ja active Active
-
2023
- 2023-03-22 JP JP2023045185A patent/JP2023085364A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180177871A1 (en) | 2018-06-28 |
AU2013229432A1 (en) | 2014-10-16 |
JP2017132821A (ja) | 2017-08-03 |
CN104159602A (zh) | 2014-11-19 |
JP6345603B2 (ja) | 2018-06-20 |
JP2015509522A (ja) | 2015-03-30 |
JP2023085364A (ja) | 2023-06-20 |
US9375471B2 (en) | 2016-06-28 |
CA2866406A1 (en) | 2013-09-12 |
WO2013132041A2 (en) | 2013-09-12 |
US20130236492A1 (en) | 2013-09-12 |
US20160263216A1 (en) | 2016-09-15 |
EP2822581A2 (en) | 2015-01-14 |
CN104159602B (zh) | 2017-10-24 |
JP2019001832A (ja) | 2019-01-10 |
JP7295895B2 (ja) | 2023-06-21 |
US9931399B2 (en) | 2018-04-03 |
US10842868B2 (en) | 2020-11-24 |
WO2013132041A3 (en) | 2014-04-10 |
RU2014140521A (ru) | 2016-04-27 |
JP2021088564A (ja) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014010417A (es) | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. | |
HK1224178A1 (zh) | 環肽作為蛋白質靶向劑 | |
HK1212249A1 (en) | Bioconjugates comprising modified antigens and uses thereof | |
MX2017001406A (es) | Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva. | |
MX2013002173A (es) | Formas farmaceuticas dirigidas de epitopos multiples para la induccion de una respuesta inmunologica frente a antigenos. | |
ZA201309386B (en) | Vaccine composition comprising an inactivated chikungunya virus strain | |
MX2016007063A (es) | Peptidos terapeuticos. | |
MX352324B (es) | Vacunas multivalentes de nanovehiculos sinteticos. | |
WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
WO2013054199A3 (en) | Cmv antigens and uses thereof | |
MX2021004211A (es) | Composiciones vacuna. | |
BR112015008417A8 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica | |
MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
EP3010340A4 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
MX2014006630A (es) | Vacuna a base toxina clostridium difficile. | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
TN2014000518A1 (en) | Reassortant btv and ahsv vaccines | |
HK1254514A1 (zh) | 用於增强疫苗接種免疫反應的方法及組合物 | |
CL2015001618A1 (es) | Adyuvante de vacunación, preparación y vacunas que lo contienen | |
MX2015015428A (es) | Eliminacion de riesgo de narcolepsia en vacunas contra influenza. | |
WO2012103444A3 (en) | Immunogenic compositions and reagents for preparing | |
EA201690378A1 (ru) | Вакцинные композиции против наркотической зависимости | |
PL3077512T3 (pl) | Immunogenne kompozycje i szczepionki pochodzące od bakteryjnych białek receptora powierzchniowego |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA |
|
FG | Grant or registration |